Medicamen Biotech Ltd.

486.90 -11.15 ▼-2.2%

29 February 2024, 04:01:00 PM
Volume: 8,093

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.medicamen.com
Market Cap 619.07 Cr.
Enterprise Value(EV) 648.09 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 9.70 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 50.22 Trailing Twelve Months Ending 2023-12
Industry PE 41.63 Trailing Twelve Months Ending 2023-12
Book Value / Share 156.81 Trailing Twelve Months Ending 2023-12
Price to Book Value 3.11 Calculated using Price: 486.90
Dividend Yield 0.21 Period Ending 2023-03
No. of Shares Subscribed 1.27 Cr. 12,714,600 Shares
FaceValue 10
About Medicamen Biotech Ltd.
Medicamen Biotech Limited was incorporated in December 1993, it is a widely held, Globaly Recognized public limited company engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. Medicamen Biotech Limited is committed to produce and provide quality medicines at competitive price for domestic as well as international markets thereby being socially responsible and rendering services to the medical fraternity since inception.

Medicamen Biotech Ltd. Delivery

Delivered Qty
Traded Qty

Medicamen Biotech Ltd. Performance

1 Day
-2.24%
1 Week
-10.50%
1 Month
-9.23%
3 Month
-23.79%
6 Month
-29.52%
1 Year
-20.08%
2 Year
-26.98%
5 Year
+20.15%
10 Year
+4408.33%

Medicamen Biotech Ltd. Fundamental Ratios

5 years 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 13.95 12.94 9.89 11.25 9.06
Return on Capital Employed (%) 19.3 16.54 12.99 12.94 10.86
Return on Assets (%) 8.8 8.36 6.46 7.11 5.87

Medicamen Biotech Ltd. Balance Sheet

Particulars 6 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 87 121 133 146 193 200
Non Curr. Liab. 1 4 8 6 1 1
Curr. Liab. 49 56 53 73 83 94
Minority Int. 0
Equity & Liab. 137 181 194 225 277 295
Non Curr. Assets 40 75 91 94 106 119
Curr. Assets 96 104 96 123 163 176
Misc. Exp. not W/O 0 2 7 8 7
Total Assets 137 181 194 225 277 295

Medicamen Biotech Ltd. Profit and Loss

Particulars 6 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 123 126 113 115 141 171
Other Income 4 2 1 2 2 2
Total Income 126 127 113 117 143 173
Total Expenditure -105 -106 -93 -91 -117 -148
PBIDT 21 21 20 26 27 25
Interest -1 -1 -2 -2 -3 -3
Depreciation -2 -3 -3 -6 -6 -7
Taxation -6 -5 -4 -3 -2 -4
Exceptional Items
PAT 12 13 12 15 15 11
Minority Interest 1
Share Associate
Other Related Items
Consolidated Net Profit 12 13 12 15 15 12
Adjusted EPS 10 11 10 12 12 10

Medicamen Biotech Ltd. Cash Flow

Particulars 5 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 4 13 13 4 -6
Cash Fr. Inv. -15 -37 -18 -8 -6
Cash Fr. Finan. -4 19 6 4 29
Net Change -14 -5 1 0 17
Cash & Cash Eqvt 9 3 4 4 21

Medicamen Biotech Ltd. Shareholding Pattern

9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 43.60 43.60 43.60 43.21 43.21 43.21 43.21 43.21 43.21
Public 56.40 56.40 56.40 56.79 56.79 56.79 56.79 56.79 56.79
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Medicamen Biotech Ltd. Announcements

Tue, 13 Feb 2024
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of publication of Un-audited Financial Results for the Quarter and Nine Months ended December 31 2023
Tue, 13 Feb 2024
Announcement under Regulation 30 (LODR)-Conversion of Securities
In accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform your good office that the Board of Directors of the Company Medicamen Biotech Limited at their meeting held today i.e February 13 2024 at 05.00 PM has inter alia considered and approved the allotment of 63 500 Equity Shares of face value of Rs. 10/- each pursuant to conversion of 63 500 Fully Convertible Warrants ("Warrants") issued as on September 12 2022 at an issue price of Rs. 709/- each by way of preferential allotment.
Mon, 12 Feb 2024
Unaudited Financial Results For The Quarter And Nine Months Ended On December 31 2023
Unaudited Financial Results for the Quarter and Nine months ended on December 31 2023

Medicamen Biotech Ltd. Technical Scans

Thu, 29 Feb 2024
High Delivery Percentage High Delivery Percentage
Higher Delivery Quantity Higher Delivery Quantity
Higher Delivery Quantity and Percentage Higher Delivery Quantity and Percentage
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity

Medicamen Biotech Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 378,183.18 1,577.95 +0.3%
Cipla Ltd. 119,792.84 1,480.35 +0.2%
Dr. Reddy's Laboratories Ltd. 107,100.71 6,424.25 -0.1%
Zydus Lifesciences Ltd. 95,405.30 941.90 +1.0%
Divi's Laboratories Ltd. 92,624.64 3,489.10 -0.7%
Torrent Pharmaceuticals Ltd. 90,256.63 2,666.80 +2.2%
Apollo Hospitals Enterprise Ltd. 87,793.47 6,105.90 -3.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 42.46 1,577.95 +0.3%
Cipla Ltd. Consolidated 2023-12 32.31 1,480.35 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 20.49 6,424.25 -0.1%
Zydus Lifesciences Ltd. Consolidated 2023-12 32.08 941.90 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-12 66.98 3,489.10 -0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 60.41 2,666.80 +2.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 111.23 6,105.90 -3.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 6.06 1,577.95 +0.3%
Cipla Ltd. Consolidated 2023-12 4.63 1,480.35 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.99 6,424.25 -0.1%
Zydus Lifesciences Ltd. Consolidated 2023-12 4.91 941.90 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-12 7.11 3,489.10 -0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 12.62 2,666.80 +2.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 13.00 6,105.90 -3.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,577.95 +0.3%
Cipla Ltd. Consolidated 2023-03 0.02 1,480.35 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,424.25 -0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 941.90 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,489.10 -0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,666.80 +2.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,105.90 -3.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,577.95 +0.3%
Cipla Ltd. Consolidated 2023-03 12.85 1,480.35 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,424.25 -0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 941.90 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,489.10 -0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,666.80 +2.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,105.90 -3.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,577.95 +0.3%
Cipla Ltd. Consolidated 2023-03 12.85 1,480.35 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,424.25 -0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 941.90 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,489.10 -0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,666.80 +2.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,105.90 -3.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,577.95 +0.3%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,480.35 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,424.25 -0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 941.90 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,489.10 -0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,666.80 +2.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,105.90 -3.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,577.95 +0.3%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,480.35 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,424.25 -0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 941.90 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,489.10 -0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,666.80 +2.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,105.90 -3.9%

Medicamen Biotech Ltd. FAQ's

What is Medicamen Biotech share price?

Can I buy Medicamen Biotech shares now?

What is the Dividend Yield of Medicamen Biotech?

What is the Market Cap of Medicamen Biotech?

What are the key metrics to analyse Medicamen Biotech?

What is the 52 Week High and Low of Medicamen Biotech?

What is the trend of Medicamen Biotech share price?